Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
102.69
+3.87+3.92%
Earnings
Up 3.9% — Reported earnings — EPS beat by 12%.
High confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 28.62% | Shs Outstand | 60.31M | Perf Week | 2.39% |
| Market Cap | 5.96B | Forward P/E | - | EPS next Y | -2.51 | Insider Trans | -35.37% | Shs Float | 50.80M | Perf Month | 11.95% |
| Enterprise Value | 5.91B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 17.39% | Perf Quarter | 54.24% |
| Income | -126.95M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 4.97 | Perf Half Y | 214.51% |
| Sales | 0.00 | P/B | 11.20 | EPS next Y | -19.01% | ROA | -23.04% | Short Interest | 8.83M | Perf YTD | 226.03% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -25.99% | 52W High | 104.27 -1.51% | Perf Year | 596.41% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -27.31% | 52W Low | 13.34 669.63% | Perf 3Y | 301.71% |
| Dividend Est. | 19.36 (18.85%) | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.35% 5.41% | Perf 5Y | 160.60% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 61.12% | Oper. Margin | 0.00% | ATR (14) | 5.09 | Perf 10Y | -85.29% |
| Dividend Ex-Date | Aug 29, 2024 | Quick Ratio | 23.76 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 63.41 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 23.76 | EPS Q/Q | -20.00% | SMA20 | 6.98% | Beta | -0.37 | Target Price | 153.25 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | 20.85% | Rel Volume | 0.24 | Prev Close | 98.82 |
| Employees | 68 | LT Debt/Eq | 0.00 | Earnings | Aug 10 | SMA200 | 94.65% | Avg Volume | 1.30M | Price | 102.69 |
| IPO Date | Aug 08, 1997 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 12.24% - | Net Debt/EBITDA | 0.41 | Volume | 308,254 | Change | 3.92% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-01-26 | Reiterated | UBS | Buy | $100 → $130 |
| Jun-02-26 | Reiterated | Piper Sandler | $75 → $180 | |
| Apr-30-26 | Reiterated | Leerink Partners | Outperform | $109 → $120 |
| Apr-29-26 | Reiterated | HC Wainwright & Co. | Buy | $40 → $120 |
| Apr-28-26 | Reiterated | UBS | Buy | $50 → $100 |
| Apr-27-26 | Reiterated | Wedbush | Outperform | $85 → $165 |
| Apr-27-26 | Reiterated | Guggenheim | Buy | $125 → $200 |
| Apr-27-26 | Reiterated | BTIG | Buy | $73 → $151 |
| Apr-15-26 | Reiterated | Wedbush | Outperform | $45 → $85 |
| Mar-13-26 | Reiterated | BTIG | Buy | $73 |
Latest News
Aug-03-26
Jul-10-26
Jul-10-2603:58PM
Jul-02-26
Jul-02-2602:30AM
Jun-27-26
Jun-27-2603:28PM
Jun-23-26
Jun-23-2606:47AM
Jun-22-26
Jun-22-2612:08PM
Jun-10-26
Company
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 21 | 13 | 6 | — | — | — | — | — | — | |
| Research and Development | 101 | 75 | 1 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -122 | -88 | -7 | — | — | — | — | — | — | |
| Interest Expense | 0 | 1 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 17 | 6 | 2 | — | — | — | — | — | — | |
| Net Income Before Taxes | -105 | -84 | -5 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -105 | -84 | -5 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -105 | -84 | -5 | — | — | — | — | — | — | |
| Net Income | -105 | -84 | -5 | — | — | — | — | — | — | |
| EPS (Recurring) | -2.31 | -4.99 | -4.44 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.31 | -4.99 | -4.44 | — | — | — | — | — | — | |
| EPS (Diluted) | -2.31 | -4.99 | -4.44 | — | — | — | — | — | — | |
| EBITDA | -105 | -82 | -5 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 46 | 17 | 14 | — | — | — | — | — | — | |
| Market Capitalization | 1,394 | 330 | 286 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Goncalves Joana | Chief Medical Officer | Jul 15 '26 | Sale | 86.28 | 7,000 | 603,937 | 32,718 | Jul 15 |
| Goncalves Joana | Chief Medical Officer | Jul 15 '26 | Option Exercise | 7.32 | 7,000 | 51,240 | 39,718 | Jul 15 |
| Agarwal Arjun | Senior Vice President, Finance | Jul 13 '26 | Option Exercise | 15.69 | 9,999 | 156,904 | 25,311 | Jul 13 |
| Agarwal Arjun | Senior Vice President, Finance | Jul 13 '26 | Sale | 84.63 | 9,999 | 846,180 | 15,312 | Jul 13 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Jul 01 '26 | Sale | 84.43 | 3,553,410 | 300,014,406 | 1,131,954 | Jul 01 |
| Sandler Laura Lee | Chief Operating Officer | Jul 01 '26 | Option Exercise | 7.80 | 5,000 | 39,000 | 241,384 | Jul 01 |
| Sandler Laura Lee | Chief Operating Officer | Jul 01 '26 | Sale | 94.42 | 5,000 | 472,079 | 236,384 | Jul 01 |
| Agarwal Arjun | Senior Vice President, Finance | Jun 22 '26 | Sale | 80.95 | 1,587 | 128,468 | 15,312 | Jun 22 |
| Goncalves Joana | Chief Medical Officer | Jun 15 '26 | Sale | 69.28 | 7,947 | 550,606 | 32,718 | Jun 15 |
| Klein Lawrence Otto | Chief Executive Officer | Jun 15 '26 | Sale | 69.69 | 1,729 | 120,494 | 925,580 | Jun 15 |
| Sandler Laura Lee | Chief Operating Officer | Jun 15 '26 | Sale | 69.69 | 600 | 41,814 | 236,384 | Jun 15 |
| Quinlan Paul T | General Counsel | Jun 15 '26 | Sale | 69.69 | 733 | 51,083 | 31,034 | Jun 15 |
| Agarwal Arjun | Senior Vice President, Finance | Jun 15 '26 | Sale | 69.69 | 395 | 27,528 | 16,899 | Jun 15 |
| Goncalves Joana | Chief Medical Officer | Jun 15 '26 | Option Exercise | 7.32 | 7,000 | 51,240 | 40,665 | Jun 15 |
| Agarwal Arjun | Senior Vice President, Finance | Jun 12 '26 | Sale | 69.72 | 9,459 | 659,508 | 17,294 | Jun 15 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.